» Articles » PMID: 31883407

The Molecular Biology of Medulloblastoma Metastasis

Overview
Journal Brain Pathol
Date 2019 Dec 29
PMID 31883407
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Medulloblastoma (MB) is the most common primary malignant brain tumor of childhood and a significant contributor to pediatric morbidity and death. While metastatic dissemination is the predominant cause of morbidity and mortality for patients with this disease, most research efforts and clinical trials to date have focused on the primary tumor; this is due mostly to the paucity of metastatic tumor samples and lack of robust mouse models of MB dissemination. Most current insights into the molecular drivers of metastasis have been derived from comparative molecular studies of metastatic and non-metastatic primary tumors. However, small studies on matched primary and metastatic tissues and recently developed mouse models of dissemination have begun to uncover the molecular biology of MB metastasis more directly. With respect to anatomical routes of dissemination, a hematogenous route for MB metastasis has recently been demonstrated, opening new avenues of investigation. The tumor micro-environment of the primary and metastatic niches has also been increasingly scrutinized in recent years, and further investigation of these tumor compartments is likely to result in a better understanding of the molecular mediators of MB colonization and growth in metastatic compartments.

Citing Articles

DHODH Inhibition Suppresses and Inhibits the Growth of Medulloblastoma in a Novel In Vivo Zebrafish Model.

Tsea I, Olsen T, Polychronopoulos P, Tummler C, Sykes D, Baryawno N Cancers (Basel). 2025; 16(24.

PMID: 39766063 PMC: 11674817. DOI: 10.3390/cancers16244162.


Epidemiology and survival of primary intracranial malignant tumor patients with drop metastasis: a population-based analysis.

Jin Y, Lu T, Liu B, Wang Y Acta Neurochir (Wien). 2024; 166(1):413.

PMID: 39412555 DOI: 10.1007/s00701-024-06309-2.


Use of Neuroendoscopy in Combination Treatment of a Three-Year-Old Patient With Primary Disseminated Medulloblastoma: A Case Report.

Ashurov J, Musa G, Kumirova E, Margaryan S, Livshitz M, Ozerov S Cureus. 2024; 16(8):e68239.

PMID: 39347241 PMC: 11439456. DOI: 10.7759/cureus.68239.


Intracerebellar administration of the chemokine Cxcl3 reduces the volume of medulloblastoma lesions at an advanced stage by promoting the migration and differentiation of preneoplastic precursor cells.

Ceccarelli M, Rossi S, Bonaventura F, Massari R, DElia A, Soluri A Brain Pathol. 2024; 35(1):e13283.

PMID: 38946128 PMC: 11669415. DOI: 10.1111/bpa.13283.


Drivers Underlying Metastasis and Relapse in Medulloblastoma and Targeting Strategies.

Holmberg K, Borgenvik A, Zhao M, Giraud G, Swartling F Cancers (Basel). 2024; 16(9).

PMID: 38730706 PMC: 11083189. DOI: 10.3390/cancers16091752.


References
1.
Thomas P, Deutsch M, Kepner J, Boyett J, Krischer J, Aronin P . Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. J Clin Oncol. 2000; 18(16):3004-11. DOI: 10.1200/JCO.2000.18.16.3004. View

2.
Moxon-Emre I, Taylor M, Bouffet E, Hardy K, Campen C, Malkin D . Intellectual Outcome in Molecular Subgroups of Medulloblastoma. J Clin Oncol. 2016; 34(34):4161-4170. DOI: 10.1200/JCO.2016.66.9077. View

3.
Pham C, Mitchell D . Know your neighbors: Different tumor microenvironments have implications in immunotherapeutic targeting strategies across MB subgroups. Oncoimmunology. 2016; 5(11):e1144002. PMC: 5139647. DOI: 10.1080/2162402X.2016.1144002. View

4.
Majzner R, Simon J, Grosso J, Martinez D, Pawel B, Santi M . Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues. Cancer. 2017; 123(19):3807-3815. DOI: 10.1002/cncr.30724. View

5.
Cavalli F, Remke M, Rampasek L, Peacock J, Shih D, Luu B . Intertumoral Heterogeneity within Medulloblastoma Subgroups. Cancer Cell. 2017; 31(6):737-754.e6. PMC: 6163053. DOI: 10.1016/j.ccell.2017.05.005. View